International Scholarly Research Notices

Research Article

High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population

Table 3

Influence of relative dose intensity on recurrence-free survival.
 > median RDI ≤ median RDITotal
Total    
 Number of pts3333 66
 Median RDI (iqr)0,92 (0,86–0,98)0,65 (0,30–0,76)0,0000,83 (0,64–0,92)
 Recurrence rate0,360,420,8010,39
 Median RFS (iqr)5,49 (2,12–7,91)5,08 (1,52–6,83)0,5905,22 (1,71–7,39)
Folfox/capox    
 Number of pts2022 42
 Median RDI (iqr)0,89 (0,84–0,95)0,71 (0,44–0,76)0,0000,82 (0,70–0,87)
 Recurrence rate0,10,360,0710,24
 Median RFS (iqr)6,94 (5,32–7,65)5,11 (2,47–6,93)0,0455,51 (3,83–7,21)
Oxaliplatin    
 Number of pts2022 42
 Median RDI (iqr)0,88 (0,74–0,95)0,50 (0,39–0,63)0,0000,67 (0,50–0,87)
 Recurrence rate0,20,270,7320,24
 Median RFS (iqr)6,94 (3,40–7,65)5,36 (3,83–6,93)0,6025,51 (3,83–7,21)
5FU    
 Number of pts1014 24
 Median RDI (iqr)1,00 (0,94–1,00)0,55 (0,26–0,87)0,0000,87 (0,36–0,99)
 Recurrence rate0,60,710,6730,67
 Median RFS (iqr)2,11 (1,11–10,21)2,63 (1,25–5,50)0,8652,55 (1,20–9,47)
RDI = relative dose intensity; pts = patients; iqr = interquartile range; RFS = recurrence-free survival; 5FU = 5-fluorouracil (also includes capecitabine).
Subanalysis of oxaliplatin RDI in patients treated with capox or folfox.